Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 4Sarcoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Pharyngeal Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1PRETEXT I Hepatoblastoma 1Neurofibromatosis 2 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Mesothelial 1Mouth Neoplasms 1Melanoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Erdheim-Chester Disease 1Endometrial Adenocarcinoma 1Endocrine Gland Neoplasms 1

Interventions

temsirolimus 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Rare Tumours × temsirolimus × 1 year × Clear all
NCT01396408 2026-03-27

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Canadian Cancer Trials Group

Phase 2 Active not recruiting
137 enrolled

Advanced Rare Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡